ArticleInternational journal of cardiology. Heart & vasculature2026
Low-dose ventricular radiotherapy in wild-type transthyretin cardiac amyloidosis: a prospective, first-in-human, exploratory clinical trial.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies.Journal of clinical medicine research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) causes heart failure through myocardial deposition of misfolded transthyretin (TTR) fibrils. Radiotherapy has been explored in localized amyloid deposition in other organs, but its potential role in ATTRwt-CA remains unexplored. Methods: Eligible patients with ATTRwt-CA underwent low-dose radiotherapy (LD-RT) (10 Gy in 5 daily fractions) targeting the left ventricle. Cardiac amyloid burden was assessed using 18F-Flutemetamol amyloid PET (tissue-to-background ratio (TBR) in the septal and lateral LV walls) and cardiac magnetic resonance (CMR) imaging (extracellular volume and T1 mapping) at baseline and 12 weeks. Additionally, New York Heart Association (NYHA) class, cardiac biomarkers, transthoracic echocardiography, 6-minute walk test (6MWT) and the Short-Form 36-Item Health Survey (SF-36) were evaluated at baseline and at weeks 3, 6, 12, and 6 months post-LD-RT. Safety was assessed through systematic clinical follow-up and monitoring of patient-reported symptoms potentially attributable to LD-RT. Results: Five patients with ATTRwt-CA (mean age 87 years) received focused LD-RT; two received concomitant tafamidis. No grade ≥ 3 treatment-related adverse events occurred over 6 months. At 12 weeks, clinical, biomarker, and functional changes were heterogeneous. A directional decrease in amyloid PET uptake ratio was observed in most patients, irrespective of tafamidis exposure, whereas native T1 values and left ventricular mass index on CMR showed no improvement. Conclusion: In this small exploratory cohort, cardiac radiotherapy was well tolerated. Although no efficacy conclusions can be drawn, the observed PET signal warrants cautious evaluation in adequately powered studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.